Subtopic Deep Dive

Oncolytic Virus Therapy for Cancer
Research Guide

What is Oncolytic Virus Therapy for Cancer?

Oncolytic virus therapy engineers viruses like herpes simplex, adenovirus, and reovirus for selective tumor cell replication, lysis, and immune stimulation in cancer treatment.

This approach modifies viruses to preferentially infect and destroy cancer cells while sparing healthy tissue, often enhancing antitumor immunity. Key viruses include ICP34.5-deleted herpes simplex virus (Liu et al., 2003, 779 citations) and engineered adenoviruses. Over 10 papers in the provided list exceed 300 citations, with Kaufman et al. (2015, 1558 citations) as the most cited review.

Curated Papers

Key Challenges

Why It Matters

Oncolytic viruses convert immunologically cold tumors to hot by inducing inflammation and T-cell infiltration, boosting checkpoint inhibitor efficacy in melanoma and glioma trials (Lawler et al., 2016; Chiocca and Rabkin, 2014). Clinical translation includes T-VEC approval for melanoma, improving survival endpoints when combined with PD-1 blockers (Kaufman et al., 2015). These therapies address immunotherapy resistance in solid tumors, with ongoing Phase III studies evaluating herpes and reovirus vectors (Bulcha et al., 2021).

Key Research Challenges

Tumor Delivery Barriers

Engineered viruses face neutralization by host antibodies and poor vascular access to hypoxic tumor cores (Waehler et al., 2007). Strategies like shielding and targeting ligands aim to improve penetration (Cattaneo et al., 2008). Clinical efficacy remains limited by these delivery hurdles in solid tumors.

Immune Evasion Limits

Rapid antiviral immunity clears oncolytic viruses before full tumor lysis, reducing therapeutic spread (Chiocca and Rabkin, 2014). Arming viruses with IL-12 or checkpoint modulators seeks to redirect immunity toward tumors (Nguyen et al., 2020). Balancing oncolysis with sustained immune stimulation poses ongoing issues.

Replication Selectivity

Ensuring tumor-selective replication without off-target effects in normal cells requires precise genetic deletions like ICP34.5 (Liu et al., 2003). Metabolic hijacking by viruses complicates selectivity in diverse cancer types (Thaker et al., 2019). Validation across patient-derived models remains critical.

Essential Papers

Oncolytic viruses: a new class of immunotherapy drugs

Howard L. Kaufman, Frederick J. Kohlhapp, Andrew Zloza · 2015 · Nature Reviews Drug Discovery · 1.6K citations

Viral vector platforms within the gene therapy landscape

Jote Bulcha, Yi Wang, Hong Ma et al. · 2021 · Signal Transduction and Targeted Therapy · 1.2K citations

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties

Binlei Liu, Max Robinson, Z-Q Han et al. · 2003 · Gene Therapy · 779 citations

Engineering targeted viral vectors for gene therapy

Reinhard Waehler, Stephen J. Russell, David T. Curiel · 2007 · Nature Reviews Genetics · 670 citations

Oncolytic Viruses in Cancer Treatment

Sean Lawler, Maria C. Speranza, Choi-Fong Cho et al. · 2016 · JAMA Oncology · 559 citations

Oncolytic viruses are an active area of clinical research. The ability of these agents to harness antitumor immunity appears to be key for their success. Combinatorial studies with immune checkpoin...

Viral hijacking of cellular metabolism

Shivani K Thaker, James Ch’ng, Heather R. Christofk · 2019 · BMC Biology · 507 citations

This review discusses the current state of the viral metabolism field and gaps in knowledge that will be important for future studies to investigate. We discuss metabolic rewiring caused by viruses...

Bacteria-cancer interactions: bacteria-based cancer therapy

Mai T. Duong, Yeshan Qin, Sung-Hwan You et al. · 2019 · Experimental & Molecular Medicine · 465 citations

Reading Guide

Foundational Papers

Start with Liu et al. (2003) for ICP34.5-deleted herpes simplex engineering (779 citations), then Waehler et al. (2007) for targeting principles, and Cross and Burmester (2006) for gene therapy history in cancer.

Recent Advances

Study Kaufman et al. (2015, 1558 citations) for immunotherapy classification, Lawler et al. (2016) for clinical translation, and Bulcha et al. (2021, 1204 citations) for viral platforms.

Core Methods

Core techniques: genetic deletions for selectivity (Liu et al., 2003), retargeting with ligands/adapters (Waehler et al., 2007), arming for immune stimulation (Chiocca and Rabkin, 2014), metabolic rewiring analysis (Thaker et al., 2019).

How PapersFlow Helps You Research Oncolytic Virus Therapy for Cancer

Discover & Search

Research Agent uses searchPapers to retrieve top-cited works like Kaufman et al. (2015) on oncolytic immunotherapy, then citationGraph maps influencers such as Liu et al. (2003) ICP34.5 deletions, and findSimilarPapers uncovers related herpes vector engineering from Waehler et al. (2007). exaSearch drills into Phase III trial data for reovirus-glioma combos.

Analyze & Verify

Analysis Agent employs readPaperContent on Chiocca and Rabkin (2014) to extract immune stimulation mechanisms, verifyResponse with CoVe cross-checks claims against Lawler et al. (2016) JAMA review, and runPythonAnalysis performs survival curve meta-analysis from trial abstracts using pandas. GRADE grading scores evidence strength for T-VEC checkpoint combinations.

Synthesize & Write

Synthesis Agent detects gaps in tumor delivery from Waehler et al. (2007) vs. recent Bulcha et al. (2021) platforms, flags contradictions in immune evasion data. Writing Agent uses latexEditText for manuscript sections, latexSyncCitations integrates 10+ references like Liu et al. (2003), and latexCompile generates trial workflow diagrams via exportMermaid.

Use Cases

"Meta-analyze survival data from oncolytic virus Phase III trials in melanoma."

Research Agent → searchPapers('oncolytic virus phase III melanoma') → Analysis Agent → runPythonAnalysis(pandas aggregation of endpoints from Kaufman 2015, Lawler 2016) → statistical p-values and forest plots output.

"Draft LaTeX review on herpes simplex oncolytic engineering."

Synthesis Agent → gap detection (Liu 2003 vs. Bulcha 2021) → Writing Agent → latexEditText(herpes section) → latexSyncCitations(Chiocca 2014) → latexCompile → camera-ready PDF with citations.

"Find GitHub code for oncolytic virus replication modeling."

Research Agent → paperExtractUrls(Thaker 2019 metabolism paper) → Code Discovery → paperFindGithubRepo → githubRepoInspect → runnable Python sims for viral hijacking kinetics.

Automated Workflows

Deep Research workflow conducts systematic review of 50+ oncolytic papers via searchPapers → citationGraph → GRADE-scored report on immunotherapy combos (Kaufman 2015). DeepScan applies 7-step CoVe analysis to verify Liu et al. (2003) ICP34.5 claims against trial data. Theorizer generates hypotheses on IL-12 armed reoviruses from Nguyen et al. (2020) + Chiocca (2014).

Try Doxa for Oncolytic Virus Therapy for Cancer Research

Frequently Asked Questions

What defines oncolytic virus therapy?

Oncolytic virus therapy uses genetically modified viruses that selectively replicate in and lyse cancer cells, often stimulating antitumor immunity (Kaufman et al., 2015).

What are key methods in this field?

Methods include ICP34.5 deletion in herpes simplex for enhanced oncolysis (Liu et al., 2003), adenovirus targeting ligands (Waehler et al., 2007), and arming with immunomodulators like IL-12 (Nguyen et al., 2020).

What are the most cited papers?

Top papers are Kaufman et al. (2015, 1558 citations) on immunotherapy drugs, Liu et al. (2003, 779 citations) on herpes engineering, and Waehler et al. (2007, 670 citations) on targeted vectors.

What open problems exist?

Challenges include overcoming antiviral immunity for better delivery, ensuring replication selectivity across tumor types, and optimizing combos with checkpoint inhibitors (Chiocca and Rabkin, 2014; Lawler et al., 2016).